IFNB1 and COVID-19: The lack of impact on recovery contrasts with the results from the phase II study of inhaled IFN-β in patients with COVID-19 [23], conducted at the beginning of the COVID-19 pandemic (March to May 2020) before any treatments that had been evaluated in randomised controlled studies were implemented as SoC.